UH Cancer Center researcher Michele Carbone won the 2026 Szent‑Györgyi Prize for work linking inherited BAP1 mutations to mesothelioma and spurring life‑saving interventions.

BLS May 2025 data show pediatric surgeons top national pay at $502,050 while cardiologists lead many state lists. The state map is dominated by medical specialties.

Modelers have removed the extreme RCP8.5/SSP5‑8.5 marker from the CMIP7 design; the revision narrows the upper‑end of projections but still leaves large warming and financial risk.

Microsoft released Defender engine and platform updates after two zero‑day flaws were spotted in the wild; CISA added the CVEs to its KEV list and set a June 3 federal remediation deadline.

The Commerce Department unveiled a $2B CHIPS‑funded quantum package that includes $1B for IBM’s new foundry and minority equity stakes in several startups.

Eli Lilly says its experimental drug retatrutide produced near‑surgical levels of weight loss in late‑stage trials, but analysts note higher side effects and access questions.

A new Frontiers study finds a small uptick in lung cancer incidence after COVID‑19, especially among current and former smokers, and points to the enzyme TYMP as a likely mechanism.

MIT leaders say federal research cuts and falling grad enrollment forced tighter budgets and fewer admissions — a shift President Sally Kornbluth calls "a striking loss."

A Lancet‑published consensus has renamed PCOS to PMOS to emphasize hormonal and metabolic causes. Patient groups are split as the three‑year roll‑out begins.

Ukrainian surgeons told Fort Bragg medics that drone swarms are stretching evacuations from minutes to days, forcing new training and underground care plans.

An LLM‑backed analysis finds D.C. and Maryland among the most exposed to AI‑driven task changes, and regional training programs are racing to respond.

Moderna, Praxis and other Massachusetts firms joined a new national alliance pushing a Vision 2030 plan to keep U.S. biotech competitive with China.

A Madison nonprofit won a federal voucher to speed FDA review of psilocybin for major depression, joining two other programs selected under an April executive order. Local researchers say the award validates years of work but leaves rollout questions.